{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:07:03Z","timestamp":1724285223123},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,21]]},"DOI":"10.7759\/cureus.67424","type":"journal-article","created":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T22:48:16Z","timestamp":1724280496000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Liver Injury Immediately After Initiation of Triple Therapy in a Patient With BRAF V600E Mutation-Positive Colorectal Cancer"],"prefix":"10.7759","author":[{"given":"Yuka","family":"Aimono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ohkawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Appropriate use guide. (2023). https.\/\/www.ono-oncology.jp\/sites\/default\/files\/2024-02\/mektovi-rmp.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-022-02264-z","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study","volume":"28","author":"Sakata H","year":"2023","unstructured":"Sakata H, Murase M, Kato T, Yamaguchi K, Sugihara K, Suzuki S, Yoshino T. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study. Int J Clin Oncol. 2023, 28:139-44. 10.1007\/s10147-022-02264-z","journal-title":"Int J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1915676","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"382","author":"Sharma V","year":"2020","unstructured":"Sharma V, Vanidassane I. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2020, 382:10.1056\/NEJMc1915676","journal-title":"N Engl J Med"},{"key":"ref5","unstructured":"Treatment manual for each serious side effect of disease. drug-induced liver injury. (2008). Accessed:  April 20, 2024: https:\/\/www.mhlw.go.jp\/topics\/2006\/11\/dl\/tp1122-1i01.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw645","article-title":"Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","volume":"28","author":"Seligmann JF","year":"2017","unstructured":"Seligmann JF, Fisher D, Smith CG, et al.. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2017, 28:562-8. 10.1093\/annonc\/mdw645","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090607","article-title":"BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis","volume":"9","author":"Chen D","year":"2014","unstructured":"Chen D, Huang JF, Liu K, et al.. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014, 9:10.1371\/journal.pone.0090607","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad A","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, et al.. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012, 483:100-3. 10.1038\/nature10868","journal-title":"Nature"},{"key":"ref9","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264642-a-case-of-liver-injury-immediately-after-initiation-of-triple-therapy-in-a-patient-with-braf-v600e-mutation-positive-colorectal-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T22:48:19Z","timestamp":1724280499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264642-a-case-of-liver-injury-immediately-after-initiation-of-triple-therapy-in-a-patient-with-braf-v600e-mutation-positive-colorectal-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.67424","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,21]]}}}